Current research uncovers pathogenic mechanisms and explores anti-fibrotic therapies for idiopathic pulmonary fibrosis, highlighting potential progression modification.
Idiopathic interstitial pneumonias (IIPs) comprise a heterogeneous group of diffuse parenchymal lung disorders, with idiopathic pulmonary fibrosis (IPF) being the most prevalent subtype. Despite its rarity, IPF is associated with a high mortality rate, driving substantial research into its etiology, pathogenesis, diagnostic strategies, and therapeutic interventions. In recent years, multiple novel agents, including the anti-fibrotic candidate PRM-151, have been explored as potential treatments aimed at modifying disease progression and improving patient outcomes.
No takes yet. Share an insight, caveat, or question.
Jianlin Lou (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: